A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Wei, Hai Xia ^a   Wei, Shan Shan ^a   Lindsay, David S ^b   Peng, Hong Juan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CHINESE DRUG; CLINDAMYCIN; CLINDAMYCIN PLUS PYRIMETHAMINE; COTRIMOXAZOLE; PYRIMETHAMINE SULFADIAZINE; SPIRAMYCIN; SULFONAMIDE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; PYRIMETHAMINE; SULFADIAZINE;

AIDS PATIENT; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; ENCEPHALITIS; HUMAN; MONOTHERAPY; PREGNANCY; SAMPLE SIZE; SEROCONVERSION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TOXOPLASMA GONDII; TOXOPLASMIC ENCEPHALITIS; TOXOPLASMOSIS; TREATMENT OUTCOME; VERTICAL TRANSMISSION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; FEMALE; MALE; META ANALYSIS; PARASITOLOGY; PREVENTION AND CONTROL; TOXOPLASMA; TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-INFECTIVE AGENTS; ANTIPROTOZOAL AGENTS; AZITHROMYCIN; CLINDAMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PREGNANCY; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE; TOXOPLASMA; TOXOPLASMOSIS; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84947425479     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138204     Document Type: Article

References (55)

1. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363(9425):1965-1976. PMID: 15194258
2. Robert-Gangneux F, Murat JB, Fricker-Hidalgo H, Brenier-Pinchart MP, Gangneux JP, Pelloux H. The placenta: a main role in congenital toxoplasmosis? Trends Parasitol. 2011; 27(12):530-536. doi: 10. 1016/j.pt.2011.09.005 PMID: 22079164
3. Moncada PA, Montoya JG. Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment. Expert review of anti-infective therapy J. 2012; 10(7):815-828.
4. Cottrell AJ. Acquired Toxoplasma encephalitis. Arch Dischild. 1986; 61: 84-85.
5. Israelski DM, Remington JS. Toxoplasmosis in non-AIDS immunocopromised host. Curr Clin Top Infect Dis. 1993; 13: 322-356. PMID: 8397917
6. Luft B J, Hafner R, Korzun AH, Leport C, Antoniskis D, Bosler EM, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. NEJM. 1993; 329: 995-1000.
7. McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009; 104: 320-44. PMID: 19430661
8. Li Y, Wu YL. How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives? Med Trop (Mars). 1998; 58(3 Suppl): 9-12.
9. Chen SX, Wu L, Jiang XG, Feng YY, Cao JP. Anti-Toxoplasma gondii activity of GAS in vitro. J Ethnopharmacol. 2008; 118(3):503-7. doi: 10.1016/j.jep.2008.05.023 PMID: 18602775
10. Yang X, Huang B, Chen J, Huang S, Zheng H, Lun ZR, et al. In vitro effects of aqueous extracts of Astragalus membranaceus and Scutellaria baicalensis GEORGI on Toxoplasma gondii. Parasitol Res. 2012; 110: 2221-2227. doi: 10.1007/s00436-011-2752-2 PMID: 22179265
11. Desmonts G, Couvreur J. Toxoplasmosis in pregnancy and its transmission to the fetus. Bull N Y Acad Med. 1974; 50:146-159. PMID: 4521728
12. Avelino MM, Amaral WN, Rodrigues IM, Rassi AR, Gomes MB, Costa TL, et al. Congenital toxoplasmosis and prenatal care state programs. BMC Infect Dis. 2014; 14:33. doi: 10.1186/1471-2334-14-33 PMID: 24438336
13. Valentini P, Buonsenso D, Barone G, Serranti D, Calzedda R, Ceccarelli M, et al. Spiramycin/cotrimoxazole versus pyrimethamine/sulfonamide and spiramycin alone for the treatment of toxoplasmosis in pregnancy. J Perinatol. 2015; 35(2):90-4. doi: 10.1038/jp.2014.161 PMID: 25211284
14. Rodrigues IM, Costa TL, Avelar JB, Amaral WN, Castro AM, Avelino MM. Assessment of laboratory methods used in the diagnosis of congenital toxoplasmosis after maternal treatment with spiramycin in pregnancy. BMC Infect Dis. 2014; 14:349. doi: 10.1186/1471-2334-14-349 PMID: 24961630
15. SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group, Thiebaut R, Leprout S, Chene G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet. 2007; 369:115-122. PMID: 17223474
16. Fung HB, Kirschenbaum HL. Treatment Regimens for Patients with Toxoplasmic Encephalitis. Clin Ther. 1996; 18: 1037-1056. PMID: 9001822
17. Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumech N. Pyrimethamine-clindamycin vs. pyrimethamine- sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. 1996; 22: 268-275. PMID: 8838183
18. Harrell M, Carvounis PE. Current treatment of toxoplasma retinochoroiditis: an evidence-based review. J Ophthalmol. 2014; 2014:273506. doi: 10.1155/2014/273506 PMID: 25197557
19. Gilbert RE, See SE, Jones LV, Stanford MS. Antibiotics versus control for Toxoplasma retinochoroiditis (Review). Cochrane Database Syst Rew. 2002; (1: ): CD002218.
20. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009; 6(6): e1000097. doi: 10. 1371/journal.pmed1000097
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539-1558. PMID: 12111919
22. Tamaru S, Kikuchi A, Takagi K, Wakamatsu M, Horikoshi T, Ogiso Y. Fetal therapy of severe symptomatic toxoplasmosis using azithromycin. J Obstet Gynaecol Res. 2011; Jul; 37(7):953-7. doi: 10.1111/j. 1447-0756.2010.01459.x Epub 2011 Mar 31. PMID: 21450026
23. Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibacterials. Drug Saf. 1993; Nov; 9 (5):346-64. PMID: 8280403
24. Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year.Am J Obstet Gynecol. 1999; 180:410-415. 15. PMID: 9988811
25. Rothova A, Bosch-Driessen LE, van Loon NH, Treffers WF. Azithromycin for ocular toxoplasmosis. Br J Ophthalmol. 1998; 82: 1306-1308. PMID: 9924338
26. Yin WD, Gao QC, Liu XD, Tang HW. In vivo Effect of Dihydroartemisinin and azithromycin on the Ultrastructure of Toxoplasma gondii Tachyzoites. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2009; 27:325-7. PMID: 20066989
27. Nagamune K, Beatty WL, Sibley LD. Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii. Eukaryot Cell. 2007; 6: 2147-56. PMID: 17766463
28. Deng JH, Fu L, Chen YS, Guo HF, Zhang JL. The soup of toxoplasmosis to treating 50 cases with toxoplasmosis in children. Journal of Traditional Chinese Medicine. 1996; 37: 102-103.
29. Wang CG. The research of treating toxoplasmosis using Artemisia annua and preliminary observations clinical treatment. Chinese Journal of Zoonoses. 1997; 13: 79-80.
30. Qi GC, Li QX, Kan QL, Tong HW, Zhang GZ, Xu WY, et al. The analysis of clinical curative effects of Qing Jing Granules on toxoplasmosis of 42 cases with infertility. Journal of Traditional Chinese Medicine. 1999; 40: 603-605.
31. Mi Y, Mi C. The treating of 70 cases toxoplasmosis in pregnancy using Astragalusannua. Shandong Journal of Traditional Chinese Medicine. 2000; 19: 83-84.
32. Sun YX, Niu HZ, Yu LX. Righting Disinfection Treatment 60 cases toxoplasmosis of women in childbearing age. Chinese Journal of Integrated Traditional and Western Medicine. 2001; 467-468.
33. Tian C, Wang WH, Yuan XH, Ren LJ, Zhang XB, Zhang XM. The clinical study of righting eliminate the original pill on toxoplasmosis. Shandong Journal of Traditional Chinese Medicine. 2004; 23: 528-529.
34. Li DH, Li YG, Zhang WJ. Clinical studies on the treatment of toxoplasmosis by the anti- toxoplasmosis decoction. Journal of Pathogen Biology. 2011; 6: 295-296.
35. Ou YW, Li M. Analysis the detection and treat of toxoplasma infection in women of childbearing age. Liuzhou Medicine. 2009; 22: 56.
36. Wang XQ, Zhu Q. The analysis of curative effects of 192 cases with toxoplasmosis. Occupation and Health. 2005; 04: 612-613.
37. Rajapakse S, Chrishan Shivanthan M, Samaranayake N, Rodrigo C, Deepika Fernando S. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health. 2013; 107 (4):162-169. doi: 10.1179/2047773213Y.0000000094 PMID: 23816507
38. Felix JP, Lira RP, Zacchia RS, Toribio JM, Nascimento MA, Arieta CE. Trimethoprim-Sulfamethoxazole Versus Placebo to Reduce the Risk of Recurrences of Toxoplasma Gondii Retinochoroiditis: Randomized Controlled Clinical Trial. American Journal of Ophthalmology. 2014; 157(4): 762-766.e1. doi: 10. 1016/j.ajo.2013.12.022 PMID: 24388839
39. Romand S, Pudney M, Derouin F. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother. 1993; 37(11): 2371-8. PMID: 8285620
40. Chang HR, Jefford CW, Pechère JC. In vitro effects of three new 1, 2, 4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii. Antimicrob Agents Chemother. 1989; 33 (10): 1748-52. PMID: 2589842
41. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, et al. (2002) Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/AgenceNationale de Recherchesur le SIDA, Essai 039. Clin Infect Dis 34:1243-1250. PMID: 11941551
42. Beraud G, Pierre-Francois S, Foltzer A, Abel S, Liautaud B, Smadja D, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. Am J Trop Med Hyg.2009; 80: 583-587. PMID: 19346380
43. Cortina-Borja M, Tan HK, Wallon M, Paul M, Prusa A, Buffolano W, et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observation prospective cohort study. PLoS Med. 2010; 7:e1000351. doi: 10.1371/journal.pmed.1000351 PMID: 20967235
44. Gras L, Wallon M, Pollak A, Cortina-Borja M, Evengard B, Hayde M, et al. Association between prenatal treatment and clinical manifestations of CT in infancy: a cohort study in 13 European centres.Acta Paediatr. 2005; 94: 1721-1731 PMID: 16421031
45. Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, Kopp CB, et al. Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis. 2013; 56(9):1223-31. doi: 10.1093/cid/cit032 PMID: 23362291
46. Meroni V, Genco F, Tinelli C, Lanzarini P, Bollani L, Stronati M, et al. Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii- specific immunoglobulin G antibodies. Clin Vaccine Immunol. 2009; 16(10):1517-20. doi: 10.1128/ CVI.00253-09 PMID: 19692628
47. Montoya JG, Remington JS. Management of Toxoplasma gondii Infection during Pregnancy. Clinical Infectious Diseases. 2008; 47:554-66. doi: 10.1086/590149 PMID: 18624630
48. Berrebi A, Bardou M, Bessieres MH, Nowakowska D, Castagno R, Rolland M, et al. Outcome for children infected with congenital toxoplasmosis in the first trimester and with normal ultrasound findings: a study of 36 cases. Eur J Obstet Gynecol Reprod Biol. 2007; 135:53-57. PMID: 17189666
49. Rabilloud M, Wallon M, Peyron F. In utero and at birth diagnosis of congenital toxoplasmosis: use of likelihood ratios for clinical management. Pediatr Infect Dis J. 2010; 29(5):421-5. doi: 10.1097/INF. 0b013e3181c80493 PMID: 19952858
50. Montoya JG, Remington JS. Management of Toxoplasma gondii Infection during Pregnancy. Clinical Infectious Diseases. 2008; 47:554-66. doi: 10.1086/590149 PMID: 18624630
51. Gilbert R, Gras L. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG. 2003; 110: 112-20. PMID: 12618153
52. Romand S, Wallon M, Franck J, Thulliez P, Peyron F, Dumon H. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol. 2001; 97:296-300. PMID: 11165598
53. Ruf B, Schurmann D, Bergmann F. Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993; 12: 325-329. PMID: 8354297
54. Jordan MK, Burstein AH, Rock-Kress D, Alfaro RM, Pau AK, Pau AK, et al. Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virusinfected patients. Antimicrobial Agents and Chemotherapy. 2004; 48: 635-637. PMID: 14742225
55. Duval X, Pajot O, Le Moing V, Longuet P, Ecobichon JL, Mentre F, et al. Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy. AIDS. 2004; 18: 1473-5571.